The EU Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) brought together a wide range of stakeholders spanning the health and medical industries on 20-21 November as part of a push to develop regulatory guidance on the use of artificial intelligence (AI).
One purpose of the joint HMA/EMA workshop, which was hosted by the agencies’ big data steering group, was to offer industry stakeholders the opportunity to voice their opinions on the EMA’s draft reflection paper on AI regulation in the medicinal product lifecycle, published in July
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?